Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren for prevention of left ventricular remodeling after high-risk acute myocardial infarction
2006-001704-37Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI), Left ventricular remodeling (LVR) and hypertension (HTN) comparing Aliskiren 300 mg + optimized standard therapy with Placebo + optimized standard therapy (2 arms). Primary endpoint: Change in left ventricular end systolic volume (LVESV). Started Oct 2006; status: completed.
02
Drugs
aliskiren
03
Conditions
myocardial infarction (MI)Left ventricular remodeling (LVR)hypertension (HTN)
Beyond the preview
Go deeper on 2006-001704-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001704-37.